Snrg Pharma Consulting (India) Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 01-11-2024
- Paid Up Capital ₹ 0.41 M
as on 01-11-2024
- Company Age 4 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue 86.20%
(FY 2023)
- Profit 88.06%
(FY 2023)
- Ebitda 62.37%
(FY 2023)
- Net Worth 171.00%
(FY 2023)
- Total Assets 84.36%
(FY 2023)
About Snrg Pharma Consulting (India)
The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.41 M, as per Ministry of Corporate Affairs (MCA) records.
Prabu Nambiar, Binesh Prabhakar, Chandra Kanisseri, and One other member serve as directors at the Company.
- CIN/LLPIN
U24297TN2020FTC139581
- Company No.
139581
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
21 Nov 2020
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Snrg Pharma Consulting (India)?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Binesh Prabhakar  | Director | 21-Nov-2020 | Current |
| Prabu Nambiar | Director | 21-Nov-2020 | Current |
Chandra Kanisseri  | Director | 21-Nov-2020 | Current |
| Lakshmanan | Director | 21-Sep-2021 | Current |
Financial Performance of Snrg Pharma Consulting (India).
Snrg Pharma Consulting (India) Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 86.2% increase. The company also saw a substantial improvement in profitability, with a 88.06% increase in profit. The company's net worth Soared by an impressive increase of 171%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Snrg Pharma Consulting (India)?
In 2023, Snrg Pharma Consulting (India) had a promoter holding of 100.00%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
One Vector Technologies Private LimitedInactive For E-Filing 6 months 10 daysBinesh Prabhakar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Snrg Pharma Consulting (India)?
Snrg Pharma Consulting (India) has a workforce of 43 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Snrg Pharma Consulting (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Snrg Pharma Consulting (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
